Navigation Links
WestPark Capital, Inc. Engaged By Alliqua, Inc.

LOS ANGELES, May 31, 2012 /PRNewswire/ --WestPark Capital, Inc., a Los Angeles based investment banking company, today announced it has signed a non-exclusive engagement agreement with Alliqua, Inc.  During the term of the engagement, WestPark Capitol shall provide advice to the company regarding business and finance, private and public equity and debt financing, and the company's relations with its securities holders and provide introductions to investors.

About Alliqua, Inc.

Alliqua Inc. (OTCBB: ALQA.OB) ("Alliqua") is an advanced biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation.  Through its wholly-owned subsidiary, Alliqua BioMedical, Inc., Alliqua intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform of AquaMed Technologies, Inc. ("AquaMed"), Alliqua's subsidiary.

AquaMed manufactures custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics.  These products use proprietary manufacturing technologies which enable AquaMed to produce what is known in the healthcare industry as high water content, electron beam cross-linked aqueous polymer sheet hydrogels.  AquaMed believes that it is one of two manufacturers in the world for these gels.  Alliqua's third subsidiary, HepaLife Biosystems, Inc., focuses on the development of a cell-based bio-artificial liver system, known as HepaMate™.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

For additional information, please visit

About WestPark Capital

WestPark Capital, Inc., ( is a full-service investment bank focused on emerging growth sectors such as healthcare, software, technology, biotechnology, financial services, manufacturing, consumer products, media and telecom industries, among other categories. WestPark provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, private placements and corporate finance advisory services. WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them. Member: FINRA/SIPC.

WestPark Capital, Inc.
Richard Rappaport, CEO
(310) 843-9300

SOURCE WestPark Capital, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. One of the Largest Wendys(R) Franchisees, Tar Heel Capital, Reduces Fraud and Slashes Costs with DigitalPersona
2. US joins over 50 nations in adopting recommendation to list vessels engaged in illegal fishing
Post Your Comments:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology: